$1.72
+0.16 (+10.26%)
Open$1.55
Previous Close$1.56
Day High$1.81
Day Low$1.55
52W High$7.92
52W Low$1.22
Volume—
Avg Volume71.4K
Market Cap24.43M
P/E Ratio—
EPS$-1.89
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,482.6% upside
Current
$1.72
$1.72
Target
$27.22
$27.22
$16.99
$27.22 avg
$37.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 181.8K | 111.5K | 4.38M |
| Net Income | -26,740,729 | -14,762,102 | -1,275,702 |
| Profit Margin | -14,755.4% | -14,017.6% | -29.1% |
| EBITDA | -26,362,859 | -15,362,029 | -1,970,058 |
| Free Cash Flow | — | — | -1,043,157 |
| Rev Growth | +63.0% | +63.0% | +7.3% |
| Debt/Equity | — | — | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |